Back to articles

Severe asthma: Updated guidelines highlight emerging treatment options


A task force convened by the European Respiratory Society (ERS) and American Thoracic Society (ATS) provided an updated definition of severe asthma, addressed treatment of patients with severe asthma through optimal use of traditional agents (e.g., corticosteroids, beta-agonists), and provided guidance on appropriate use of emerging and/or targeted therapies, including omalizumab (Xolair—Genentech/Novartis), macrolide antibiotics, methotrexate, and antifungal agents.